Using R For Flexible Modelling Of Pre-Clinical Combination Studies

More documents

Recommendations

Info

Modelling Drug Combinations • Why? • The theory • An example • The practicalities in R AstraZeneca Discovery Statistics 2 Chris Harbron, Using R For Flexible Modelling Of Pre-Clinical Combination Studies, USE-R 2009
Why Drug Combinations? • Making better use of our assets • Some marketed compounds are combinations e.g. Symbicort • In some disease areas, e.g oncology, HIV, polypharmacy is the norm • Compounds licensed only for use in combination with a specific other agent • Lapatinib (GSK – Breast cancer) is approved for use in combination with capecitabine • Increased molecular & pathway level understanding • Hypothesise and understanding synergistic actions • Link with systems biology AstraZeneca Discovery Statistics 3 Chris Harbron, Using R For Flexible Modelling Of Pre-Clinical Combination Studies, USE-R 2009
Page 1: Using R For Flexible Modelling Of P
Page 5 and 6: Combination Studies [B] Benefit? :
Page 7 and 8: Interaction Index - Berenbaum Combi
Page 9 and 10: Interaction Index - Berenbaum Combi
Page 11 and 12: Unified Tau ⎧ d ⎪ D ⎪ 1 = ⎨
Page 13 and 14: EDA Suggests Synergy At Higher Dose
Page 15 and 16: Estimates Of Synergy With 95% CIs O
Page 17 and 18: Flexibly Building Formula Varying n
Page 19 and 20: mynls() : A less temperamental nls(
Page 21 and 22: mynls() : A less temperamental nls(
Page 23: Summary • Early identification of

Using R For Flexible Modelling Of Pre-Clinical Combination Studies

Create successful ePaper yourself

Delete template?

Save as template?